ORCHPHARMA

Orchid Pharma Share Price

₹1,811.20 +32.75 (1.84%)

28 Dec, 2024 02:20

SIP TrendupStart SIP in ORCHPHARMA

Start SIP

Performance

  • Low
  • ₹1,778
  • High
  • ₹1,854
  • 52 Week Low
  • ₹703
  • 52 Week High
  • ₹1,854
  • Open Price₹1,778
  • Previous Close₹1,778
  • Volume53,320

Investment Returns

  • Over 1 Month + 15.36%
  • Over 3 Month + 32.08%
  • Over 6 Month + 48.98%
  • Over 1 Year + 152.87%
SIP Lightning

Smart Investing Starts Here Start SIP with Orchid Pharma for Steady Growth!

Invest Now

Orchid Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 77.2
  • PEG Ratio
  • 3.2
  • Market Cap Cr
  • 9,186
  • P/B Ratio
  • 7.9
  • Average True Range
  • 68.96
  • EPS
  • 23.46
  • Dividend Yield
  • 0
  • MACD Signal
  • 72.61
  • RSI
  • 63.82
  • MFI
  • 74.89

Orchid Pharma Financials

Orchid Pharma Technicals

EMA & SMA

Current Price
₹1,811.20
+ 32.75 (1.84%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹1,722.55
  • 50 Day
  • ₹1,603.08
  • 100 Day
  • ₹1,485.53
  • 200 Day
  • ₹1,309.62

Resistance and Support

1814.5 Pivot Speed
  • R3 1,925.95
  • R2 1,889.90
  • R1 1,850.55
  • S1 1,775.15
  • S2 1,739.10
  • S3 1,699.75

What's your outlook on Orchid Pharma?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Orchid Pharma is a leading pharmaceutical company in India, specializing in the manufacture of active pharmaceutical ingredients (APIs) and generic formulations. It serves global markets with a focus on antibiotics, anti-inflammatory, and central nervous system therapies.

Orchid Pharma has an operating revenue of Rs. 904.80 Cr. on a trailing 12-month basis. An annual revenue growth of 24% is outstanding, Pre-tax margin of 11% is healthy, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 10%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 15% and 49% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 11% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 59 which is a POOR score indicating inconsistency in earnings, a RS Rating of 87 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 57 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Orchid Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-11 Quarterly Results
2024-08-12 Quarterly Results
2024-05-23 Audited Results
2024-02-08 Quarterly Results
2023-11-04 Quarterly Results

Orchid Pharma F&O

Orchid Pharma Shareholding Pattern

69.84%
16.78%
0.81%
1.94%
0.12%
7.59%
2.92%

About Orchid Pharma

  • NSE Symbol
  • ORCHPHARMA
  • BSE Symbol
  • 524372
  • Managing Director
  • Mr. Manish Dhanuka
  • ISIN
  • INE191A01027

Similar Stocks to Orchid Pharma

Orchid Pharma FAQs

Orchid Pharma share price is ₹1,811 As on 28 December, 2024 | 02:06

The Market Cap of Orchid Pharma is ₹9186.2 Cr As on 28 December, 2024 | 02:06

The P/E ratio of Orchid Pharma is 77.2 As on 28 December, 2024 | 02:06

The PB ratio of Orchid Pharma is 7.9 As on 28 December, 2024 | 02:06

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23